Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
about
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patientsCyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patientsMultimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the LiteratureUK guidelines for the management of bone sarcomasManagement of Ewing sarcoma family of tumors: Current scenario and unmet needEfficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysisDiagnosis and treatment of Ewing sarcoma of the bone: a review articleReceptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas.Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.New strategies in ewing sarcoma: lost in translation?What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group - EWING1Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.Do long term survivors of ewing family of tumors experience low bone mineral density and increased fracture risk?UK Guidelines for the Management of Bone Sarcomas.Ewing sarcoma of the bone in children under 6 years of ageDo patients with ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity?Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.Primary extraosseous intracranial Ewing's sarcoma: Case report and literature review.Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology GroupMolecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.Current management of pediatric soft tissue sarcomas.Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeExtraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal ManagementTargeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.Tumor resection at the pelvis using three-dimensional planning and patient-specific instruments: a case series.What Sport Activity Levels Are Achieved in Patients After Resection and Endoprosthetic Reconstruction for a Proximal Femur Bone Sarcoma?Role of chemotherapy in the management of soft tissue sarcomas.Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.Approaching Ewing sarcoma.Ewing sarcoma: clinical state-of-the-art.Diagnosis and prognosis for the Ewing family of tumors.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Cellular immunotherapy strategies for Ewing sarcoma.
P2860
Q24186938-55D78208-A079-4A91-8460-83181B53CA46Q24202196-DF664558-6834-4016-9835-8C86F38CC336Q26740437-CC27554B-D19E-4740-8AB2-63060F6EA8A2Q26752425-3EA06DCD-042F-41F1-9FE8-15FB2B5B40A6Q28073218-394D2B34-1F84-42F7-B7DA-2BBA51206A23Q28084433-C32D7BA9-DBA0-4D19-8F68-A7310D2AE7F1Q28085071-8B3D68A9-0FD9-4B4A-97D7-7D744756617DQ30315828-EF9FDEFF-042E-4262-B495-E485702F8C0EQ33274572-C9B29026-A2C0-4758-B011-A5F10539E0F5Q33403469-DB5CBDA2-78A9-4ED4-AFCD-3C757A38A324Q33404428-31AC7C29-0DC9-47BF-A156-853D6AFC9E29Q33417823-772AE6C3-05AB-4630-BEE4-D48D58EDB43CQ33758471-89646E98-BA16-467A-91F8-A253DBBD4E77Q33805175-E6456ED2-D386-4E39-8EFF-FE9E7ADB77E7Q33839052-5EC9B8DA-90BE-4315-9958-7D5208AC6CEEQ34276911-E27EA4A4-3BE8-4BD3-87A4-C048035D7E4FQ34496992-0119250F-D0C6-4C98-A1D3-CFEF84F1F036Q34575191-97F93E4A-810A-4A43-AB4D-814175EF6B09Q35050301-4190115A-77C3-4C9D-91B0-587DFF35ADCBQ35131440-9C848466-07B9-492D-9C47-71AF635BF842Q35214578-2B81B434-B7CD-4EED-B7C9-B01FDE07A235Q35584126-A68DE6CE-8AB3-4C3F-AA05-55B6A125E454Q35610855-9AD776BF-5C2F-4BBB-8473-BF0672B60C1AQ35688154-F3091FB4-AEB4-47A0-A1CE-3DC0878E21ECQ35957998-06C0BBBB-047A-4311-8933-9F9A0D9C35B9Q36233316-70968C6C-D465-4CBE-9B84-A3B3B22D6397Q36262280-26FFF84D-D877-4554-B1C1-AD4206D15352Q36265620-1ACADC7B-B082-4420-8B28-814D3C2A5526Q36844984-90DE6648-A709-4251-B8CB-D5ADE13DDA2FQ37269236-C9299184-5BEA-49DF-ADB2-BB95329D19FDQ37326192-F56F05BD-B572-40EC-BA13-31F354EA7ED1Q37621255-7558BD97-52DF-4438-A2C4-FE9340EB71D7Q37687389-097C88DD-38E3-4A2A-B148-4F85D4103142Q37688646-20EF0725-5576-4A27-B199-829BD00459CEQ37771959-0E4911A5-118A-431C-B561-E5EC20DDC273Q37980482-9A9F08DA-A7CC-40CF-BD41-1CFA27761D98Q38088856-1A6D6B06-6D54-43B3-BEB5-9ADDD50E670EQ38112088-3D7C3067-6C01-45D0-9E12-BD437E4ACB1FQ38113988-4C229846-4156-4E54-8EAA-AD1E30A5B135Q38217594-00CBFC73-6F61-46E9-927D-E1C2EAC837B3
P2860
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@en
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@nl
type
label
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@en
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@nl
prefLabel
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@en
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@nl
P2093
P356
P1476
Results of the EICESS-92 Study ...... eatment in high-risk patients.
@en
P2093
Alan W Craft
Allan Hackshaw
Andrea Hunold
Andreas Schuck
Andreas Zoubek
Anna Cassoni
Anne McTiernan
Carolyn Douglas
David Spooner
European Intergroup Cooperative Ewing's Sarcoma Study-92
P304
P356
10.1200/JCO.2008.16.5720
P407
P577
2008-09-01T00:00:00Z